Welcome to our dedicated page for Geovax Labs SEC filings (Ticker: GOVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GeoVax Labs, Inc. filings document a clinical-stage biotechnology issuer developing multi-antigenic vaccines and immunotherapies for infectious diseases and cancer. The company’s regulatory disclosures cover operating and financial results, research and development activity, clinical and regulatory updates for programs such as GEO-MVA, GEO-CM04S1 and Gedeptin, and risks associated with development-stage biotechnology operations.
Its SEC record also includes proxy materials on governance, executive compensation and equity awards; registration statements and 8-K reports covering common stock, warrants, registered offerings and other capital-structure matters; and material-event disclosures related to agreements, reporting status and shareholder voting matters.
GeoVax Labs, Inc. filed a Post-Effective Amendment No. 3 to its Form S-1 to add Exhibit 23.1 (Consent of Independent Registered Public Accounting Firm) that was inadvertently omitted from the prior post-effective amendment. The filing includes an estimated expense schedule totaling $16,135 (SEC registration fee $635).
The document also discloses recent issuances of restricted common stock and private placement agreements, including issuance of 11,883, 4,892 and 6,703 restricted shares in 2023–2024 and private placement commitments for up to 11,904,768 common shares issuable upon exercise of warrants (September 30, 2025) and up to 865,804 such shares (February 12, 2026). The amendment is signed by the CEO and principal officers.
GeoVax Labs, Inc. filed Post-Effective Amendment No. 3 to its Form S-1 to add Exhibit 23.1 (consent of independent registered public accounting firm) that was omitted from the prior post-effective amendment.
The filing also lists estimated issuance expenses, including an $1,034 SEC registration fee and $16,534 total expenses. It discloses recent unregistered issuances: 11,883, 4,892 and 6,703 restricted shares issued under service/consulting agreements, and private placement commitments for up to 11,904,768 shares issuable upon warrant exercise and up to 865,804 shares issuable upon exercise under a February 12, 2026 purchase agreement.
GeoVax Labs, Inc. filed a Post-Effective Amendment No. 3 to its Form S-1 (File No. 333-281973) to add Exhibit 23.1, the consent of its independent registered public accounting firm, which was inadvertently omitted from the prior post-effective amendment.
The filing also lists estimated issuance expenses totaling $16,093 and discloses prior private sales of restricted common stock and warrants issuable upon exercise on specified dates.